Wolfe Research Upgrades MoonLake Immunotherapeutics (NASDAQ:MLTX) to Outperform
MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) was upgraded by analysts at Wolfe Research from a “peer perform” rating to an “outperform” rating in a report released on Monday, MarketBeat Ratings reports. The firm presently has a $61.00 price target on the stock. Wolfe Research’s price objective would indicate a potential upside of 51.44% from […]
MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) was upgraded by analysts at Wolfe Research from a “peer perform” rating to an “outperform” rating in a report released on Monday, MarketBeat Ratings reports. The firm presently has a $61.00 price target on the stock. Wolfe Research’s price objective would indicate a potential upside of 51.44% from […]
